Structure-guided approach identifies a novel class of HIV-1 ribonuclease H inhibitors: binding mode insights through magnesium complexation and site-directed mutagenesis studies
HIV persistent infection requires a life-long treatment and among the 2.1 million new
HIV infections that occur every year there is an increased rate of transmitted drugresistant
mutations. This fact requires a constant and timely effort in order to identify
and develop new HIV inhibitors endowed with innovative mechanisms. The HIV-1
Reverse Transcriptase (RT) associated Ribonuclease H (RNase H) is the only viral
encoded enzymatic activity that still lacks an efficient inhibitor despite the fact that it